Search Results
Oct 28, 2025, 08:11 ET Fosun Pharma Announces 2025Q3 Financial Results
a potential best-in-class (BIC) broad-spectrum anti-tumor antibody-drug conjugate (ADC) that combines dual mechanisms of action—immune checkpoint blockade and payload-mediated cytotoxicity. As the world's first PD-L1 ADC developed for TETs, HLX43 has demonstrated promising preliminary efficacy in the
More news about: Fosun Pharma
Oct 28, 2025, 08:00 ET POLYN Technology Announces First Silicon-Implemented NASP™ Chip
Ultra-low latency: 50 microseconds per inference Fully asynchronous operation: no clock, no ADC/DAC conversion POLYN's NASP technology and design tools give semiconductor and AI developers a new way
More news about: Polyn
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
continuous flow manufacturing, oligonucleotide synthesis, biocatalysis, Corynex® protein expression technology, antibody drug conjugations (ADC) and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients' needs. Learn more:
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
continuous flow manufacturing, oligonucleotide synthesis, biocatalysis, Corynex® protein expression technology, antibody drug conjugations (ADC) and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients' needs. Learn more:
More news about: Ajinomoto Bio-Pharma Services
Oct 27, 2025, 14:27 ET Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development
The OEB-5 rated suite will accelerate ADC development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing Syngene's existing
More news about: Syngene International
Oct 27, 2025, 07:15 ET ADC Therapeutics to Present at November Investor Conferences
for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment
More news about: ADC Therapeutics SA
Oct 27, 2025, 07:00 ET Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®) and third line therapy amivantamab (EGFR-cMET bispecific RYBREVANT®) - Combination
More news about: Actinium Pharmaceuticals, Inc.
Oct 27, 2025, 06:41 ET Antibody-Drug Conjugates Market to Surge to US $30.42 Billion by 2033, Fueled by Next-Gen Targeted Oncology Therapies | According to DataM Intelligence
reshape treatment paradigms as new approvals broaden the ADC therapeutic footprint. By Technology Type Linker and payload technologies remain the backbone of ADC innovation. Cleavable linker systems currently
More news about: DataM Intelligence 4 Market Research LLP
Oct 26, 2025, 21:00 ET Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA
More news about: Antengene Corporation Limited
Oct 24, 2025, 12:30 ET Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
highly expressed targets across solid tumors, reinforcing its potential as a clinically meaningful pan-tumor ADC target, and further support development of HWK-007, Whitehawk's PTK7-directed ADC candidate. Key findings include:
More news about: Whitehawk Therapeutics, Inc.
Oct 24, 2025, 12:18 ET 再鼎醫藥公布Zocilurtatug Pelitecan（前稱ZL-1310）最新一期臨床數據， 顯示其成為同類首創用於小細胞肺癌的靶向DLL3 ADC的潛力，並啟動全球三期注冊研究
再鼎醫藥總裁，全球研發負責人Rafael G. Amado博士表示：「Zoci表現出的強勁且持久的抗腫瘤活性，以及良好的安全性特征，凸顯了其有望成為治療SCLC的同類最佳靶向 DLL3 ADC。這一項目在不到兩年時間從1期研究推進至全球注冊性研究，體現了我們團隊的速度、對科學的嚴謹與卓越的執行力，標志著再鼎醫藥推進全球項目的重要裡程碑。我們正快速將zoci拓展至其他存在高度未滿足需求的領域，包括小細胞肺癌一線治療和神經內分泌癌，這兩個項目預計將在明年進入注冊性研究階段。」 本次報告披露了包括1期單藥劑量遞增和劑量擴展階段的共6個劑量組的115例患者（0.8 mg/kg、1.2 mg/kg、1.6
More news about: 再鼎醫藥
Oct 24, 2025, 04:40 ET Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
bispecific ADC for later-line treatment of recurrent/metastatic nasopharyngeal carcinoma is an important milestone of iza-bren and will lead global nasopharyngeal carcinoma treatment into the ADC era. Dr. Jonathan Cheng reviewed the journey of the EGFR×HER3 bispecific ADC from target
More news about: eChinaHealth
Oct 23, 2025, 02:18 ET 最大里程碑付款到賬 一家中國醫藥MNC強勢崛起
方文峰供職於中國著名的中山大學腫瘤防治中心，他們對iza-bren進行了長達數年的臨床研究。在一項經過其他藥物一線治療、且未接受化療的50名局晚期或轉移性EGFR突變NSCLC的研究中，iza-bren控制腫瘤不復發的時間超過一年——比現有全球最優治療方案延長了近一倍。 10月中旬的歐洲腫瘤內科學會（ESMO）2025 年會，再次帶來了iza-bren的好消息。這款全球首創 EGFR×HER3 雙抗 ADC 藥物，首次報告了其關鍵註冊 III 期臨床研究的成果：該藥物在後線鼻咽癌治療核心療效指標上實現了成倍的提升。研究成果也在國際頂級醫學期刊《柳葉刀》（The Lancet）發表全文。 目前，iza-bren已在全球開展 40 余項臨床研究，其中包括10
More news about: Biokin
Oct 22, 2025, 11:37 ET Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC
Iza-bren's unique bispecific ADC technology and its ability to target two high-value antigens (EGFR and HER3) have endowed it with strong efficacy and broad applicability. This has attracted multinational pharma giants facing looming patent cliffs and eager to expand their ADC portfolios. BMS reached a
More news about: Biokin
Oct 21, 2025, 20:25 ET Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
Innovent will grant Takeda exclusive rights for IBI343 (CLDN18.2 ADC) outside Greater China. Innovent will grant Takeda an exclusive option for the rights for IBI3001 (EGFR/B7H3 ADC) outside Greater China. Innovent will receive a US$1.2
More news about: Innovent Biologics
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
About PADCEV™ (enfortumab vedotin)PADCEV™ (enfortumab vedotin) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.7 Nonclinical data suggest
More news about: Astellas Pharma Inc.
Oct 21, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics
continuous flow manufacturing, oligonucleotide synthesis, biocatalysis, Corynex® protein expression technology, antibody drug conjugations (ADC) and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients' needs. Learn more:
More news about: Ajinomoto Bio-Pharma Services
Oct 21, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics
continuous flow manufacturing, oligonucleotide synthesis, biocatalysis, Corynex® protein expression technology, antibody drug conjugations (ADC) and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients' needs. Learn more:
More news about: Ajinomoto Bio-Pharma Services
Oct 20, 2025, 08:33 ET GlycoNex Abstract on Glycan-Directed ADC GNX1021 Accepted for Presentation at AACR-NCI-EORTC 2025
glycan-directed cancer immunotherapies, today announced that an abstract describing preclinical research on its first-in-class antibody-drug conjugate (ADC), GNX1021, has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October
More news about: GlycoNex, Inc.
Oct 20, 2025, 04:57 ET The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 20, 2025, 04:30 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
("Antengene", SEHK: 6996.HK) today announced the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 ADC), were presented in a Poster Presentation at ESMO 2025.
More news about: Antengene Corporation Limited
Oct 20, 2025, 02:44 ET ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
representing a significant area of clinical unmet need. Chinese researchers have been at the forefront of exploring HER2-ADC therapy for UC. The HER2-ADC disitamab vedotin was first approved in China in 2021 for the treatment of HER2-overexpressing (IHC 2+/3+) advanced or metastatic urothelial
More news about: RemeGen Co., Ltd
Oct 20, 2025, 02:20 ET Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
accepted, comprising one oral presentation, one mini oral, eight posters, and one e-poster. Notably, an LBA featuring Hengrui's antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) compared with pyrotinib plus capecitabine for patients with HER2-positive advanced or metastatic breast cancer was
More news about: Hengrui Pharma
Oct 20, 2025, 01:44 ET Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 1 ADC project approved for marketing and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 22:01 ET Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC project approved for marketing and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.